Company / Cash & Equivalents
United Therapeutics Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.6B
FY2025
5-year range
$894.8M / $1.7B
FY2021-FY2025
Trend
-8.3%
vs FY2024
Sector context
#14 of 207
Health Care
What the data says
Among 207 Health Care companies, United Therapeutics is in the top 7% for cash & equivalents. Improved from $1.2B to $1.6B over the past 2 years.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 5-year CAGR of +16.1%. Top quartile in the Health Care sector.
Improved from $1.2B to $1.6B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +17.4%
- 5-Year CAGR
- +16.1%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 207This company $1.6B Sector average $669.5M
▼
+132.6% above sector average
Key checks
Key Insights
- 5-year CAGR of +16.1%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 8.3% year-over-year.
- Ranks #14 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | -8.3% |
| FY2024 | $1.7B | +40.5% |
| FY2023 | $1.2B | +25.6% |
| FY2022 | $961.2M | +7.4% |
| FY2021 | $894.8M | +21.1% |
| FY2020 | $738.7M | +0.0% |
| FY2019 | $738.4M | +10.3% |
| FY2018 | $669.2M | -19.5% |
| FY2017 | $831.8M | -18.7% |
| FY2016 | $1.0B | +23.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026